Research programme: angiogenesis inhibitors - Cellceutix

Drug Profile

Research programme: angiogenesis inhibitors - Cellceutix

Alternative Names: PMX-20005

Latest Information Update: 12 Sep 2013

Price : $50

At a glance

  • Originator PolyMedix
  • Class Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Age-related macular degeneration; Cancer; Inflammation

Most Recent Events

  • 09 Sep 2013 Suspended - Preclinical for Age-related macular degeneration, Cancer and Inflammation in USA (unspecified route)
  • 04 Sep 2013 Cellceutix has acquired the assets of PolyMedix
  • 01 Apr 2013 PolyMedix files for Chapter 7 bankruptcy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top